A zebrafish model of tauopathy allows in vivo imaging of neuronal cell death and drug evaluation

Journal of Clinical Investigation

Volumn 119, Issue 5, 2009, Pages 1382-1395

  Paquet, Dominik ^a   Bhat, Ratan ^b   Sydow, Astrid ^c   Mandelkow, Eva Maria ^c   Berg, Stefan ^b   Hellberg, Sven ^b   Fälting, Johanna ^b   Distel, Martin ^d   Köster, Reinhard W ^d   Schmid, Bettina ^a   Haass, Christian ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b ASTRAZENECA R AND D   (Sweden)

^c MAX PLANCK UNIT FOR STRUCTURAL MOLECULAR BIOLOGY   (Germany)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3 CHLORO 4 HYDROXYANILINO) 3 (2 NITROPHENYL)MALEIMIDE; AR 164; AR 534; FLUORESCENT DYE; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; LITHIUM CHLORIDE; TAU PROTEIN; UNCLASSIFIED DRUG; ENZYME INHIBITOR; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; MAPT PROTEIN, HUMAN; PHOTOPROTEIN; RED FLUORESCENT PROTEIN; SYNAPTOTAGMIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR DISORDER; CELL DEATH; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DEMENTIA; DOWN REGULATION; DRUG DESIGN; DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; EXPERIMENTAL MODEL; IN VIVO STUDY; LARVA; MICROSCOPY; MOLECULAR IMAGING; NERVE CELL NECROSIS; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN PHOSPHORYLATION; TAUOPATHY; TRANSGENIC ANIMAL; ZEBRA FISH; ANIMAL; ANIMAL EMBRYO; CHEMICAL STRUCTURE; CHEMISTRY; CONGENITAL MALFORMATION; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; ESCAPE BEHAVIOR; GENETICS; HISTOLOGY; HUMAN; METABOLISM; METHODOLOGY; MOTONEURON; NERVE CELL; PATHOLOGY; PHOSPHORYLATION; SEQUENCE ALIGNMENT; SPINAL CORD;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; CELL DEATH; DISEASE MODELS, ANIMAL; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; EMBRYO, NONMAMMALIAN; ENZYME INHIBITORS; ESCAPE REACTION; GLYCOGEN SYNTHASE KINASE 3; HUMANS; LARVA; LUMINESCENT PROTEINS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; MOTOR NEURONS; NEURONS; PHOSPHORYLATION; PROTEIN CONFORMATION; SEQUENCE ALIGNMENT; SPINAL CORD; SYNAPTOTAGMINS; TAU PROTEINS; TAUOPATHIES; ZEBRAFISH;

EID: 66449115032     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI37537     Document Type: Article

References (47)

1. Haass, C., and Selkoe, D.J. 2007. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 8:101-112.
2. Kosik, K.S., Joachim, C.L., and Selkoe, D.J. 1986. Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 83:4044-4048.
3. Grundke-Iqbal, I., et al. 1986. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. U. S. A. 83:4913-4917.
4. Braak, H., and Braak, E. 1991. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82:239-259.
5. Santacruz, K., et al. 2005. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 309:476-481.
6. Hutton, M., et al. 1998. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 393:702-705.
7. Mandelkow, E.M., and Mandelkow, E. 1998. Tau in Alzheimer's disease. Trends Cell Biol. 8:425-427.
8. Gotz, J., and Ittner, L.M. 2008. Animal models of Alzheimer's disease and frontotemporal dementia. Nat. Rev. Neurosci. 9:532-544.
9. Zon, L.I., and Peterson, R.T. 2005. In vivo drug discovery in the zebrafish. Nat. Rev. Drug Discov. 4:35-44.
10. Jeong, J.Y., et al. 2008. Functional and developmental analysis of the blood-brain barrier in zebrafish. Brain Res. Bull. 75:619-628.
11. Tomasiewicz, H.G., Flaherty, D.B., Soria, J.P., and Wood, J.G. 2002. Transgenic zebrafish model of neurodegeneration. J. Neurosci. Res. 70:734-745.
12. Bai, Q., Garver, J.A., Hukriede, N.A., and Burton, E.A. 2007. Generation of a transgenic zebrafish model of tauopathy using a novel promoter element derived from the zebrafish eno2 gene. Nucleic Acids Res. 35:6501-6516.
13. Mazanetz, M.P., and Fischer, P.M. 2007. Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat. Rev. Drug Discov. 6:464-479.
14. Bhat, R., et al. 2003. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J. Biol. Chem. 278:45937-45945.
15. Winklhofer, K.F., Tatzelt, J., and Haass, C. 2008. The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases. EMBO J. 27:336-349.
16. Urasaki, A., Morvan, G., and Kawakami, K. 2006. Functional dissection of the Tol2 transposable element identified the minimal cis-sequence and a highly repetitive sequence in the subterminal region essential for transposition. Genetics. 174:639-649.
17. Koster, R.W., and Fraser, S.E. 2001. Tracing transgene expression in living zebrafish embryos. Dev. Biol. 233:329-346.
18. Walhout, A.J., et al. 2000. GATEWAY recombinational cloning: application to the cloning of large numbers of open reading frames or ORFeomes. Methods Enzymol. 328:575-592.
19. Park, H.C., et al. 2000. Analysis of upstream elements in the HuC promoter leads to the establishment of transgenic zebrafish with fluorescent neurons. Dev. Biol. 227:279-293.
20. Kosik, K.S., et al. 1988. Epitopes that span the tau molecule are shared with paired helical filaments. Neuron. 1:817-825.
21. Goedert, M., et al. 1994. Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: identification of phosphorylation sites in tau protein. Biochem. J. 301:871-877.
22. Seubert, P., et al. 1995. Detection of phosphorylated Ser262 in fetal tau, adult tau, and paired helical filament tau. J. Biol. Chem. 270:18917-18922.
23. Greenberg, S.G., Davies, P., Schein, J.D., and Binder, L.I. 1992. Hydrofluoric acid-treated tau PHF proteins display the same biochemical properties as normal tau. J. Biol. Chem. 267:564-569.
24. Hasegawa, M., et al. 1996. Characterization of mAb AP422, a novel phosphorylation-dependent monoclonal antibody against tau protein. FEBS Lett. 384:25-30.
25. Biernat, J., et al. 1992. The switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serine-proline motifs upstream of the microtubule binding region. EMBO J. 11:1593-1597.
26. Jicha, G.A., Berenfeld, B., and Davies, P. 1999. Sequence requirements for formation of conformational variants of tau similar to those found in Alzheimer's disease. J. Neurosci. Res. 55:713-723.
27. Furutani-Seiki, M., et al. 1996. Neural degeneration mutants in the zebrafish, Danio rerio. Development. 123:229-239.
28. Thies, E., and Mandelkow, E.M. 2007. Missorting of tau in neurons causes degeneration of synapses that can be rescued by the kinase MARK2/Par-1. J. Neurosci. 27:2896-2907.
29. Terwel, D., et al. 2005. Changed conformation of mutant Tau-P301L underlies the moribund tauopathy, absent in progressive, nonlethal axonopathy of Tau-4R/2N transgenic mice. J. Biol. Chem. 280:3963-3973.
30. Trevarrow, B., Marks, D.L., and Kimmel, C.B. 1990. Organization of hindbrain segments in the zebrafish embryo. Neuron. 4:669-679.
31. Fox, M.A., and Sanes, J.R. 2007. Synaptotagmin I and II are present in distinct subsets of central synapses. J. Comp. Neurol. 503:280-296.
32. Myers, P.Z., Eisen, J.S., and Westerfield, M. 1986. Development and axonal outgrowth of identified motoneurons in the zebrafish. J. Neurosci. 6:2278-2289.
33. Smith, D.G., et al. 2001. 3-Anilino-4-arylmaleimides: potent and selective inhibitors of glycogen synthase kinase-3 (GSK-3). Bioorg. Med. Chem. Lett. 11:635-639.
34. Hong, M., Chen, D.C., Klein, P.S., and Lee, V.M. 1997. Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. J. Biol. Chem. 272:25326-25332.
35. Doble, B.W., and Woodgett, J.R. 2003. GSK-3: tricks of the trade for a multi-tasking kinase. J. Cell Sci. 116:1175-1186.
36. Stachel, S.E., Grunwald, D.J., and Myers, P.Z. 1993. Lithium perturbation and goosecoid expression identify a dorsal specification pathway in the pregastrula zebrafish. Development. 117:1261-1274.
37. Geling, A., Steiner, H., Willem, M., Bally-Cuif, L., and Haass, C. 2002. A gamma-secretase inhibitor blocks Notch signaling in vivo and causes a severe neurogenic phenotype in zebrafish. EMBO Rep. 3:688-694.
38. Gerhard, G.S., et al. 2002. Life spans and senescent phenotypes in two strains of Zebrafish (Danio rerio). Exp. Gerontol. 37:1055-1068.
39. Roberts, R.C. 1961. The lifetime growth and reproduction of selected strains of mice. Heredity. 16:369-381.
40. Koster, R.W., and Fraser, S.E. 2001. Direct imaging of in vivo neuronal migration in the developing cerebellum. Curr. Biol. 11:1858-1863.
41. Mullins, M.C., Hammerschmidt, M., Haffter, P., and Nusslein-Volhard, C. 1994. Large-scale mutagenesis in the zebrafish: in search of genes controlling development in a vertebrate. Curr. Biol. 4:189-202.
42. Kimmel, C.B., Ballard, W.W., Kimmel, S.R., Ullmann, B., and Schilling, T.F. 1995. Stages of embryonic development of the zebrafish. Dev. Dyn. 203:253-310.
43. Bevis, B.J., and Glick, B.S. 2002. Rapidly maturing variants of the Discosoma red fluorescent protein (DsRed). Nat. Biotechnol. 20:83-87.
44. Kawakami, K. 2005. Transposon tools and methods in zebrafish. Dev. Dyn. 234:244-254.
45. Nüsslein-Volhard, C., and Dahm, R. 2002. Zebrafish: a practical approach. Oxford University Press. Oxford, United Kingdom. 303 pp.
46. Mocanu, M.M., et al. 2008. The potential for betastructure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous Tau in inducible mouse models of tauopathy. J. Neurosci. 28:737-748.
47. Cecchelli, R., et al. 1999. In vitro model for evaluating drug transport across the blood-brain barrier. Adv. Drug Deliv. Rev. 36:165-178.